Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1846 results
October 2020
-
Press release
New Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid… -
Press release
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6…
September 2020
-
Featured News
Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines. -
Featured News
World Heart Day 2020: From our heart to yours
September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world. -
Story Access to Healthcare
Chagas disease: Breaking the silence
Explaining Chagas disease through the stories of patients in Latin America.
-
Ad hoc release
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel,… -
Story Patient Perspectives
Speaking Up in CML
Lisa, a patient living with CML, shares her experience and discusses the importance of speaking up about unmet needs in your disease.
-
Press release
Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score – confirming substantial benefit for premenopausal women with HR+/HER2- advanced… -
Press release
Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a… -
Press release
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 … -
Featured News
Novartis at ESMO
Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)
-
Press release
Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1 Adjuvant…